Table 2.
Time at risk and observed outcomes by state populations.
| From general population | From diagnosed with COVID-19 | From hospitalised with COVID-19 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Follow-up in days | To diagnosis with COVID-19 | To hospitalised with COVID-19 | To death | Follow-up in days | To hospitalised with COVID-19 | To death | Follow-up in days | To death | ||
| Median (min, IQR, max) | Events (cumulative incidence at 67 days) | Events (cumulative incidence at 67 days) | Events (cumulative incidence at 67 days | Median (min, IQR, max) | Events (cumulative incidence at 45 days) | Events (cumulative incidence at 45 days) | Median (min, IQR, max) | Events (cumulative incidence at 45 days) | ||
| All | 67 (1, 67–67, 67) | 102,002 (1.83%) | 8041 (0.14%) | 11,327 (0.20%) | 35 (0, 19–44, 66) | 8860 (9.06%) | 2581 (3.01%) | 36 (0, 25–43, 65) | 2692 (19.16%) | |
| Age | Under 18 | 67 (1, 67–67, 67) | 4536 (0.47%) | 34 (0.0035%) | 9 (0.00093%) | 29 (0, 16–40, 65) | 40 (0.96%) | <5 | 28 (0, 19–41.75, 55) | <5 |
| Age | 18–39 | 67 (1, 67–67, 67) | 30,530 (2.13%) | 426 (0.03%) | 80 (0.0056%) | 37 (0, 22 to 44, 66) | 850 (2.91%) | 5 (0.031%) | 36 (0, 26.75–43, 65) | 11 (1.15%) |
| Age | 40–59 | 67 (1, 67–67, 67) | 44,493 (2.49%) | 1776 (0.10%) | 657 (0.037%) | 37 (0, 22–44, 66) | 3441 (8.05%) | 63 (0.18%) | 37 (0, 29–43, 65) | 142 (3.54%) |
| Age | 60–69 | 67 (1, 67–67, 67) | 10,305 (1.67%) | 1558 (0.25%) | 1026 (0.17%) | 34 (0, 14–44, 65) | 1673 (16.82%) | 131 (1.51%) | 38 (0, 30–44, 64) | 292 (10.80%) |
| Age | 70–79 | 67 (1, 67–67, 67) | 6120 (1.31%) | 2162 (0.46%) | 1967 (0.42%) | 24 (0, 7–40, 65) | 1602 (27.21%) | 406 (8.07%) | 37 (0, 26–43, 65) | 822 (24.97%) |
| Age | 80 or older | 67 (1, 67–67, 67) | 6018 (1.93%) | 2085 (0.67%) | 7588 (2.43%) | 16 (0, 7–31, 62) | 1254 (21.72%) | 1976 (40.84%) | 27 (0, 14–39.5, 65) | 1424 (51.31%) |
| Sex | Male | 67 (1, 67–67, 67) | 42,996 (1.56%) | 4602 (0.17%) | 5655 (0.21%) | 35 (0, 16–44, 66) | 4871 (11.80%) | 1114 (3.13%) | 37 (0, 26–43, 65) | 1617 (20.46%) |
| Sex | Female | 67 (1, 67–67, 67) | 59,006 (2.09%) | 3439 (0.12%) | 5672 (0.20%) | 35 (0, 20–44, 66) | 3989 (7.06%) | 1467 (2.93%) | 36 (0, 24 to 43, 65) | 1075 (17.43%) |
| Region | Barcelona | 67 (1, 67–67, 67) | 82,702 (1.98%) | 7201 (0.17%) | 8694 (0.21%) | 36 (0, 19–44, 66) | 7604 (9.56%) | 2164 (3.10%) | 37 (0, 26–43, 65) | 2393 (19.20%) |
| Region | Girona | 67 (1, 67–67, 67) | 9929 (1.78%) | 432 (0.078%) | 942 (0.17%) | 35 (0, 18–44, 66) | 657 (6.99%) | 217 (2.55%) | 32 (0, 17–41, 65) | 158 (17.48%) |
| Region | Lleida | 67 (2, 67–67, 67) | 5621 (1.52%) | 211 (0.057%) | 728 (0.20%) | 33 (0, 16–43, 65) | 391 (7.35%) | 108 (2.45%) | 35 (0, 22–41, 64) | 94 (22.27%) |
| Region | Tarragona | 67 (1, 67–67, 67) | 3748 (0.77%) | 196 (0.04%) | 958 (0.20%) | 30 (0, 16–42, 66) | 207 (5.82%) | 92 (3.00%) | 33 (0, 22–42, 64) | 45 (15.92%) |
| Charlson | 0 | 67 (1, 67–67, 67) | 80,214 (1.76%) | 3627 (0.08%) | 1613 (0.035%) | 36 (0, 21–44, 66) | 5385 (7.01%) | 365 (0.55%) | 37 (0, 29–43, 65) | 583 (8.20%) |
| Charlson | 1 | 67 (1, 67–67, 67) | 8996 (2.25%) | 1036 (0.26%) | 1607 (0.40%) | 33 (0, 15–43, 65) | 1031 (11.93%) | 519 (6.82%) | 36 (0, 23–43, 65) | 427 (24.22%) |
| Charlson | 2 | 67 (2, 67–67, 67) | 6846 (1.91%) | 1409 (0.39%) | 2304 (0.64%) | 30 (0, 11–43, 65) | 1164 (17.70%) | 460 (8.16%) | 36 (0, 23–43, 65) | 559 (25.21%) |
| Charlson | 3+ | 67 (1, 67–67, 67) | 5946 (2.20%) | 1969 (0.73%) | 5803 (2.15%) | 19 (0, 7–36, 64) | 1280 (22.53%) | 1237 (25.66%) | 31 (0, 17–41, 65) | 1123 (41.51%) |
| Autoimmune condition | 67 (2, 67–67, 67) | 6251 (2.29%) | 806 (0.29%) | 1285 (0.47%) | 34 (0, 16–44, 64) | 727 (12.10%) | 275 (5.09%) | 35 (0, 22–42, 65) | 326 (25.11%) | |
| Chronic kidney disease | 67 (1, 67–67, 67) | 3934 (1.95%) | 1408 (0.70%) | 3710 (1.84%) | 19 (0, 7–35, 62) | 892 (23.67%) | 887 (27.36%) | 31 (0, 17–41, 64) | 819 (42.57%) | |
| COPD | 67 (2, 67–67, 67) | 2359 (1.97%) | 740 (0.62%) | 1457 (1.22%) | 22 (0, 8–40, 65) | 463 (20.64%) | 261 (13.68%) | 33 (0, 19–42, 65) | 363 (36.26%) | |
| Dementia | 67 (1, 67–67, 67) | 1933 (4.54%) | 429 (1.01%) | 2701 (6.35%) | 15 (0, 8–25, 59) | 294 (15.92%) | 990 (64.07%) | 21 (0.5, 12 to 34, 65) | 376 (64.59%) | |
| Heart disease | 67 (1, 67–67, 67) | 10,732 (2.01%) | 2611 (0.49%) | 5686 (1.07%) | 28 (0, 10–41, 65) | 1903 (18.46%) | 1175 (13.20%) | 34 (0, 19–42, 65) | 1324 (34.22%) | |
| Hyperlipidemia | 67 (1, 67–67, 67) | 10,820 (2.10%) | 1498 (0.29%) | 1580 (0.31%) | 34 (0, 15–43, 65) | 1507 (14.48%) | 381 (4.18%) | 37 (0, 27–43, 65) | 508 (20.40%) | |
| Malignant neoplasm | 67 (1, 67–67, 67) | 5595 (1.92%) | 1327 (0.46%) | 3751 (1.29%) | 29 (0, 10–42, 65) | 991 (18.37%) | 588 (12.70%) | 34 (0, 20–43, 65) | 670 (34.19%) | |
| Obesity | 67 (1, 67–67, 67) | 20,761 (2.24%) | 3216 (0.35%) | 3184 (0.34%) | 33 (0, 14–43, 66) | 3103 (15.52%) | 695 (3.94%) | 37 (0, 25–43, 65) | 1088 (20.03%) | |
| Type 2 diabetes | 67 (2, 67–67, 67) | 6000 (1.89%) | 1644 (0.52%) | 2612 (0.82%) | 25 (0, 8–41, 64) | 1284 (22.30%) | 590 (11.77%) | 35 (0, 22–42, 65) | 710 (28.50%) | |
Counts of less than 5 have been obscured to protect patient privacy.
COPD chronic obstructive pulmonary disease, IQR interquartile range.